A Case of Lung Adenocarcinoma with Autoimmune Hemolytic Anemia Developing After Immune Checkpoint Inhibitor Treatment-Reference-Cited by-同舟云学术

A Case of Lung Adenocarcinoma with Autoimmune Hemolytic Anemia Developing After Immune Checkpoint Inhibitor Treatment

Published:2021-12-20 Issue:7 Volume:61 Page:975-978
ISSN:0386-9628
Container-title:Haigan
language:en
Short-container-title:JJLC

Author:

Takata Naoki¹,Kambara Kenta¹,Tokui Kotaro¹,Taka Chihiro¹,Okazawa Seisuke¹,Imanishi Shingo¹,Miwa Toshiro¹,Hayashi Ryuji²,Sato Tsutomu³,Tanaka Hiroaki⁴,Inomata Minehiko¹

Affiliation:

1. First Department of Internal Medicine, Toyama University Hospital

2. Department of Medical Oncology, Toyama University Hospital

3. Department of Hematology, Toyama University Hospital

4. Department of Internal Medicine, Shinseikai Toyama Hospital

Publisher

Japan Lung Cancer Society

Subject

Pulmonary and Respiratory Medicine,Oncology

Link

https://www.jstage.jst.go.jp/article/haigan/61/7/61_975/_pdf

Reference13 articles.

1. 1. Robilliard B, Arnaud E, Gastaud L, Broner J. A case of pembrolizumab-induced autoimmune haemolytic anaemia with polymyalgia rheumatica. Eur J Cancer. 2018; 103: 281-283.

2. 2. Okawa S, Kayatani H, Fujiwara K, Ozeki T, Takada K, Iwamoto Y, et al. Pembrolizumab-induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in Non-small Cell Lung Cancer. Intern Med. 2019; 58: 699-702.

3. 3. Williams H, Aitchison R. Pembrolizumab-induced autoimmune haemolytic anaemia and cholangitis. BMJ Case Rep. 2019; 12: e232505.

4. 4. Tanios GE, Doley PB, Munker R. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. Eur J Haematol. 2019; 102: 157-162.

5. 5. 亀崎豊実. 自己免疫性溶血性貧血. 日内会誌. 2014; 103: 1599-1608.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antineoplastics;Reactions Weekly;2022-06